Navigation Links
OncoGenex Pharmaceuticals Announces Issuance of Key Patent for OGX-011
Date:8/10/2009

BOTHELL, WA, and VANCOUVER, Aug. 10 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), today announced that the United States Patent and Trademark Office (PTO) has issued United States Patent Number 7,569,551 entitled "Chemo-and Radiation-sensitization of Cancer by Antisense TRPM-2 Oligodeoxynucleotides," on the method of using OncoGenex' lead cancer drug candidate, OGX-011, to treat certain cancers. The patent, licensed from The University of British Columbia, includes coverage for the method for treating cancers that express the protein clusterin using OGX-011, or any other clusterin antisense oligonucleotide, in combination with any chemotherapeutic agent or radiation therapy.

"The issuance of this patent expands our intellectual property estate for treating clusterin-expressing cancers using antisense therapy and provides us with a broad patent that applies well beyond prostate cancer," said Scott Cormack, President and CEO of OncoGenex. "Importantly, given that our current Phase 3 plans include combining OGX-011 with chemotherapy, this patent directly relates to our current method of using OGX-011."

OncoGenex Pharmaceuticals, Inc. owns or has licenses to approximately 67 granted or issued U.S. and foreign patents, and approximately 140 pending U.S. and foreign patent applications worldwide. Composition of matter patents covering OGX-011, OGX-427, SN2310, CSP-9222 and TOCOSOL(TM) have issued in the U.S. and certain other jurisdictions. Additional patent applications covering all of these products, as well as other technologies, are pending in the U.S. and certain other countries. TRPM-2 is an historical name for clusterin, and survives in some of the earlier patent filings.

About OncoGenex Pharmaceuticals

OncoGenex is a biopharmaceutical company committed to the development and c
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. OncoGenex Reports Second Quarter 2009 Financial Results
2. OncoGenex Pharmaceuticals to Release Second Quarter 2009 Financial Results
3. OncoGenex Pharmaceuticals Completes $9.5 Million Registered Direct Offering
4. OncoGenex Pharmaceuticals to Raise $9.5 Million Through Sale of Common Stock
5. OncoGenex Pharmaceuticals Added to Russell Indexes
6. OncoGenex Pharmaceuticals Files Shelf Registration Statement
7. OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer
8. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
9. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
10. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
11. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... 16, 2013 Oven Industries, Inc. has ... and temperature sensors since 1964. Expertly designed, ... industrial control system applications. As one of ... a generic, control loop feedback system, which helps minimize ... to adjust a systematic process, using a control element, ...
(Date:5/16/2013)... 2013 A new selection of ... Cole-Parmer is designed to meet the dynamic needs ... The new Cole-Parmer® MS-3400 Centrifuges are ... lab. They ensure a powerful and complete separation ... Their standard four-place swinging buckets hold 50-mL tubes. ...
(Date:5/16/2013)... 2013 Kitware , a ... announces new Phase II SBIR funding from the ... of an open-source, high performance computing (HPC) simulation ... enables researchers to select only the toolkits and ... computation, or analysis tasks. , Manufacturers increasingly ...
(Date:5/16/2013)...  The registration deadline has been extended until May ... National Conference, the premier conference for bioscience financial officers. ... Hilton San Diego Bayfront. "We are ... want to make sure as many people as possible ... Roberts , Chief Financial Officer of Mast Therapeutics, ...
Breaking Biology Technology:New PID Temperature Controllers Announced by Oven Industries Inc. 2Cole-Parmer Offers Enhanced Selection of Centrifuges 2Kitware Develops a Customizable Simulation Framework to Provide HPC for Small to Mid-Sized Manufacturers 2Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 2Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 3Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 4
... May 28 Clontech Laboratories, Inc., a wholly-owned subsidiary ... 1, 2009) release of the Xfect(TM) and Xfect(TM) Stem ... biodegradable nanoparticles that permit superior transfection efficiency of plasmid ... transfections can be carried out entirely in the presence ...
... efficacy of SpyGlass System for diagnostic and therapeutic ... Boston Scientific Corporation (NYSE: BSX ) ... data analyses involving the SpyGlass(R) Direct Visualization System ... which runs from May 30 to June 4 ...
... California, and AMSTERDAM, May 28 ,Agendia, a world ... support of Genentech,s Citizen,s Petition. Filed on December ... vitro diagnostic,tests be held to one set of ... 2009, Agendia formally submitted a letter of support ...
Cached Biology Technology:Clontech Laboratories, Inc. Releases the Xfect(TM) and Xfect(TM) Stem Transfection Reagents 2Boston Scientific's SpyGlass(R) Direct Visualization System Featured in Broad Range of Clinical Studies at Upcoming Digestive Disease Week(R) 2Boston Scientific's SpyGlass(R) Direct Visualization System Featured in Broad Range of Clinical Studies at Upcoming Digestive Disease Week(R) 3Boston Scientific's SpyGlass(R) Direct Visualization System Featured in Broad Range of Clinical Studies at Upcoming Digestive Disease Week(R) 4Boston Scientific's SpyGlass(R) Direct Visualization System Featured in Broad Range of Clinical Studies at Upcoming Digestive Disease Week(R) 5Boston Scientific's SpyGlass(R) Direct Visualization System Featured in Broad Range of Clinical Studies at Upcoming Digestive Disease Week(R) 6Agendia Supports Genentech's Citizen's Petition Urging FDA to Hold In-Vitro Diagnostic Tests to One Set of Scientific and Regulatory Standards 2
(Date:5/16/2013)... entirety of an individual,s DNA is examined to look ... health problems is a massively useful technology for diagnosing ... problems if used incorrectly, say new recommendations from the ... today (16 May 2013) in the European Journal ... genome and on exome* sequencing and analysis are now ...
(Date:5/16/2013)... , May 16, 2013 ... report is available in its catalogue: ... & Opportunities, 2018 http://www.reportlinker.com/p01181929/Global-Biometric-Systems-Market-Forecast--Opportunities-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Security_Systems ... and old security practises such as photographs, ... growth of biometric technologies in last few ...
(Date:5/15/2013)... In the largest clinical trial to date to examine ... carriers with diseases other than breast and ovarian cancer, ... against advanced pancreatic and prostate cancers. Results of the ... Medicine at the University of Pennsylvania and Sheba Medical ... the American Society of Clinical Oncology,s annual meeting in ...
Breaking Biology News(10 mins):European Society of Human Genetics urges caution over use of new genetic sequencing techniques 2Global Biometric Systems Market Forecast & Opportunities, 2018 2Global Biometric Systems Market Forecast & Opportunities, 2018 3Global Biometric Systems Market Forecast & Opportunities, 2018 4Global Biometric Systems Market Forecast & Opportunities, 2018 5Global Biometric Systems Market Forecast & Opportunities, 2018 6Global Biometric Systems Market Forecast & Opportunities, 2018 7PARP inhibitor shows activity in pancreatic, prostate cancers among patients carrying BRCA mutations 2
... -- Three researchers at the Albert Einstein College of ... Research Foundation (BCRF). Drs. Thomas Rohan, Susan Horwitz and ... its ongoing effort to support the advancement of breast ... is its mission, which is to achieve prevention and ...
... years. Now, with growing dependency on foreign oils and ... of a fuel revolution that could reach pumps all ... at some gas stations. However, their availability varies from ... produced. Sources of biomass for biofuel production in each ...
... the impact of Hurricane Katrina on soil quality and agriculture? ... To what extent can biofuels help make America energy independent? ... at the International Annual Meetings of the American Society of ... Science Society of America (SSSA) Nov. 4-8, 2007 at the ...
Cached Biology News:Einstein researchers receive grants totaling $700,000 for innovative breast cancer research 2The race for biofuels driving alternative sources of biomass 2Food and environmental sustainability focus of ASA-CSSA-SSSA Annual Meetings 2
RayBio Human Atherosclerosis Antibody Array 1.1 (4) with Accessory, detects 40 inflammatory factors (for lysate) Class: Antibody Array Products Product Group: Antibody Array...
Ultra Pure Grade. Used in conjunction with IPTG to identify bacterial colonies that contain recombinant plasmids by blue/white selection. X-Gal forms an intense blue precipitate in the presence of be...
Request Info...
4-Hydroxy-3-nitrophenylacetyl hapten is conjugated to SSA (Sheep serum albumin) lysine through amide bonds. This product is homologous to NP-BSA....
Biology Products: